Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness
Open accessThe DOI matches its Crossref record.
Abstract
Human papillomavirus (HPV) is the main risk factor for invasive cervical cancer. High risk ratios are found in cross-sectional data on HPV prevalence. The question raised is whether this present evidence is sufficient for making firm recommendations on HPV screening. A validated cervical cancer screening model was extended by adding HPV infection as a possible precursor of cervical intraepithelial neoplasia (CIN). Two widely different model quantifications were constructed so that both were compatible with the observed HPV risk ratios. One model assumed a much longer duration of HPV infection before progressing to CIN and a higher sensitivity of the HPV test than the other. In one version of the model, the calculated mortality reduction from HPV screening was higher and the (cost-)effectiveness was much better than for Pap smear screening. In the other version, outcomes were the opposite, although the cost-effectiveness of the combined HPV + cytology test was close to that of Pap smear screening. Although small follow-up studies and studies with limited strength of design suggest that HPV testing may well improve cervical cancer screening, only large longitudinal screening studies on the association between HPV infection and the development of neoplasias can give outcomes that would enable a firm conclusion to be made on the (cost-)effectiveness of HPV screening. Prospective studies should address women aged 30-60 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fone, D., Hollinghurst, S., Temple, M., Round, A., Lester, N., Weightman, A., Roberts, K., Coyle, E., Bevan, G., & Palmer, S. (2003) · Journal of Public Health · doi:10.1093/pubmed/fdg075 · Cited by 553
Management of women who test positive for high-risk types of human papillomavirus: the HART study
Cuzick, J., Szarewski, A., Cubie, H., Hulman, G., Kitchener, H., Luesley, D., McGoogan, E., Menon, U., Terry, G., Edwards, R., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14955-0 · Cited by 510
Wallin, K.-L., Wiklund, F., Ångström, T., Bergman, F., Stendahl, U., Wadell, G., Hallmans, G., & Dillner, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911253412201 · Cited by 493
Myers, E. R., McCrory, D. C., Nanda, K., Bastian, L., & Matchar, D. B. (2000) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010166 · Cited by 470
“The model also can be used to investigate the impact of testing for high-risk HPV types in screening strategies (49).”
BackgroundMethodBenefits and Costs of Using HPV Testing to Screen for Cervical Cancer
Mandelblatt, J. S. (2002) · JAMA · doi:10.1001/jama.287.18.2372 · Cited by 308
Goldie, S. J., Grima, D., Kohli, M., Wright, T. C., Weinstein, M., & Franco, E. (2003) · International Journal of Cancer · doi:10.1002/ijc.11334 · Cited by 209
Goldie, S. J., Kim, J. J., & Wright, T. C. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000120143.50098.c7 · Cited by 209
The MISCAN-COLON Simulation Model for the Evaluation of Colorectal Cancer Screening
Loeve, F., Boer, R., van Oortmarssen, G. J., van Ballegooijen, M., & Habbema, J. D. F. (1999) · Computers and Biomedical Research · doi:10.1006/cbmr.1998.1498 · Cited by 199
Self-citationCost-effectiveness of primary HPV screening for cervical cancer in Germany—a decision analysis
Sroczynski, G., Schnell-Inderst, P., Mühlberger, N., Lang, K., Aidelsburger, P., Wasem, J., Mittendorf, T., Engel, J., Hillemanns, P., Petry, K. U., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.03.006 · Cited by 40
Metadata
- Authors
- van Ballegooijen, M., van den Akker-van Marle, M., Warmerdam, P., Meijer, C., Walboomers, J., & Habbema, J.
- Venue
- British Journal of Cancer
- Published
- 1997-09
- Volume
- 76
- Issue
- 5
- Pages
- 651-657
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1984554475
- Cited by
- 80
- References
- 0
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.